Canadian Action On Rare Disease Is A ‘Step Forward,’ Says Industry
Executive Summary
Canadian rare disease drugs strategy is expected to improve access to treatments and the collection and use of real-world evidence.
You may also be interested in...
Companies Need EU Funding To Cover ‘Enormous Expenditure’ Of Complying With Revised GMP Rules
Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.
IGBA Welcomes Mexican Membership
The IGBA has welcomed Mexican pharmaceutical industry association ANAFAM as an associate member.
UK Considers US -Style Payment Reporting Obligations For Drug And Device Firms
The UK pharmaceutical industry association, the ABPI, would like to see its own system strengthened to improve reporting of payments to health care professionals and organizations.